CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PharmaTimes
Original article

First patient treated in new heavy‑chain‑only antibody trial

Trial StartKJ-103Positive
AI Analysis

Summary

Trax Pharmaceuticals has initiated a clinical trial of KJ-103, a heavy-chain-only antibody, with first patient treatment in TROP2-positive cancer patients.

Clinical Trial Data

Outcome Details

First patient treated in clinical trial

Importance:4/10
Sentiment:
0.30
heavy-chain-only antibodyTROP2clinical trialoncology
Related Companies

Read the original article

Published by PharmaTimes on August 17, 2026 11:15 AM

Read Original